O'Donoghue JA - Search Results

1

First-in-Human Evaluation of Site-Specifically Labeled ⁸⁹Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.

Yeh R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, Min R, Park S, Brockway JP, Bromberg JF, Zhi WI, Robson ME, Sanford R, Modi S, Agnew BJ, Lyashchenko SK, Lewis JS, Ulaner GA, Zeglis BM. Yeh R, et al. Among authors: o donoghue ja. J Nucl Med. 2024 Mar 1;65(3):386-393. doi: 10.2967/jnumed.123.266392. J Nucl Med. 2024. PMID: 38272704 Free PMC article.

2

A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer.

Pandit-Taskar N, O'Donoghue JA, Chetty D, Max S, Wanik D, Ilovich O, Russell M, Nyima T, Divgi CR, Yu M, Morris MJ. Pandit-Taskar N, et al. Among authors: o donoghue ja. J Nucl Med. 2024 Jul 1;65(7):1051-1056. doi: 10.2967/jnumed.124.267416. J Nucl Med. 2024. PMID: 38782459 Free PMC article.

3

Imaging with [⁸⁹Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.

Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT. Tendler S, et al. Lancet Oncol. 2024 Aug;25(8):1015-1024. doi: 10.1016/S1470-2045(24)00249-3. Epub 2024 Jun 28. Lancet Oncol. 2024. PMID: 38950555 Clinical Trial.

4

[¹⁸F]TFB PET/CT misses intense [¹²⁴I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer.

Backhaus P, Pentlow KS, Ho AL, Mauguen A, Fagin JA, Pillarsetty NVK, Lyashchenko SK, Burnazi E, Ghossein RA, Chhabra S, Abusamra M, Larson SM, Schöder H, O'Donoghue J, Weber W, Grewal RK. Backhaus P, et al. EJNMMI Res. 2024 Oct 8;14(1):91. doi: 10.1186/s13550-024-01138-x. EJNMMI Res. 2024. PMID: 39377970 Free PMC article.

5

Tumor Burden Assessment with Positron Emission Tomography with.

Akhurst T, Ng V V, Larson SM, O'Donoghue JA, O'Neel J, Erdi Y, Divgi CR. Akhurst T, et al. Clin Positron Imaging. 2000 Mar;3(2):57-65. doi: 10.1016/s1095-0397(00)00041-8. Clin Positron Imaging. 2000. PMID: 10838401

6

How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design.

Kiess AP, O'Donoghue J, Uribe C, Bodei L, Hobbs RF, Hesterman J, Kesner AL, Sgouros G; RPT-TEC group. Kiess AP, et al. J Clin Oncol. 2024 May 20;42(15):1734-1737. doi: 10.1200/JCO.23.01241. Epub 2024 Mar 14. J Clin Oncol. 2024. PMID: 38484205 No abstract available.

7

A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer.

Laccetti AL, Bodei L, O'Donoghue JA, Weber WA, Morris MJ. Laccetti AL, et al. Among authors: o donoghue ja. Clin Nucl Med. 2023 Nov 1;48(11):937-944. doi: 10.1097/RLU.0000000000004818. Clin Nucl Med. 2023. PMID: 37812518 Clinical Trial.

8

Lesion Dosimetry for [¹⁷⁷Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer.

Grkovski M, O'Donoghue JA, Imber BS, Andl G, Tu C, Lafontaine D, Schwartz J, Thor M, Zelefsky MJ, Humm JL, Bodei L. Grkovski M, et al. Among authors: o donoghue ja. J Nucl Med. 2023 Nov;64(11):1779-1787. doi: 10.2967/jnumed.123.265763. Epub 2023 Aug 31. J Nucl Med. 2023. PMID: 37652541 Free PMC article.

9

Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using ⁸⁹Zr-Trastuzumab PET: A Pilot Study.

Lumish MA, Maron SB, Paroder V, Chou JF, Capanu M, Philemond S, O'Donoghue JA, Schöder H, Lewis JS, Lyashchenko SK, Pandit-Taskar N, Janjigian YY. Lumish MA, et al. Among authors: o donoghue ja. J Nucl Med. 2023 May;64(5):724-730. doi: 10.2967/jnumed.122.264470. Epub 2022 Nov 23. J Nucl Med. 2023. PMID: 36418168 Free PMC article.

10

Correction to: [⁸⁹Zr]Zr‑huJ591 immuno‑PET targeting PSMA in IDH mutant anaplastic oligodendroglioma.

Krebs S, Grommes C, McDevitt MR, Carlin SD, O'Donoghue JA, Graham MS, Young RJ, Schöder H, Gutin PH, Bander NH, Osborne JR. Krebs S, et al. Among authors: o donoghue ja. Eur J Nucl Med Mol Imaging. 2022 May;49(6):2102. doi: 10.1007/s00259-022-05736-6. Eur J Nucl Med Mol Imaging. 2022. PMID: 35266033 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters